about
Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosisActive specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trialsIncreased Transendothelial Transport of CCL3 Is Insufficient to Drive Immune Cell Transmigration through the Blood-Brain Barrier under Inflammatory Conditions In Vitro.Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DCClinical use of dendritic cells for cancer therapy.Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells.Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients.mRNA-based gene transfer as a tool for gene and cell therapy.Acute myeloid leukaemia of mixed megakaryocytic and erythroid origin: a case report and review of the literature.CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.Can cell therapy heal a spinal cord injury?Immunotherapy of hematological malignancies using dendritic cells.Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cellsImmunotherapy of acute myeloid leukemia: current approaches.Dendritic cell-based cancer gene therapy.Results of a phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation.Recognition of cellular implants by the brain's innate immune system.Current challenges for the advancement of neural stem cell biology and transplantation research.Stem cell therapy for multiple sclerosis: preclinical evidence beyond all doubt?Natural killer cell immune escape in acute myeloid leukemia.A hypogranular variant of acute promyelocytic leukaemia showing a heterogenic immunophenotype with CD34, CD2, HLA-DR positivity: a case report and review of the literature.Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.Dendritic cells: cellular mediators for immunological toleranceTackling the physiological barriers for successful mesenchymal stem cell transplantation into the central nervous system.Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.Concise Review: Innate and Adaptive Immune Recognition of Allogeneic and Xenogeneic Cell Transplants in the Central Nervous System.The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cellsmRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.In vivo IL13-primed macrophages contribute to reduced alloantigen-specific T cell activation and prolong immunological survival of allogeneic mesenchymal stem cell implants.Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells.Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use.Cefepime and amikacin as empirical therapy in patients with febrile neutropaenia: a single-centre phase II prospective survey.Intracerebral transplantation of interleukin 13-producing mesenchymal stem cells limits microgliosis, oligodendrocyte loss and demyelination in the cuprizone mouse model.Interleukin-13 immune gene therapy prevents CNS inflammation and demyelination via alternative activation of microglia and macrophages.Immunomodulatory Effects of 1,25-Dihydroxyvitamin D3 on Dendritic Cells Promote Induction of T Cell Hyporesponsiveness to Myelin-Derived Antigens.Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium.Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.
P50
Q27008133-877769E4-5E2E-4C9C-ABE0-209E5A71A84CQ27026836-5024AFE6-A636-44B3-A223-18F55F5D76B2Q33775611-B88F6C59-5F44-42D7-92DD-645408B1B19EQ33940675-B2741CFB-A1AD-450A-9FFD-7B0DB61F53BFQ34421850-91F69C0F-0D43-412F-9225-5475433911CEQ36915744-E0471929-11D2-4469-BF20-E433E5A86F9AQ36919825-CC46C4E4-A56F-4030-83DF-E8ECBC2A07A3Q36969188-F9E3D4C2-D8CB-4B5B-8855-A32F7651E752Q37070951-0FB4C989-5C76-4B99-B19B-6D203CA66179Q37078990-76A14524-584A-4D0D-B4FB-A1018F407DA1Q37112511-561E236A-59F4-475F-BDAA-20A4BCF83B3AQ37129083-E6625EB9-80D5-4447-AA4C-90C6ECBF2825Q37294760-C0F14272-4168-441F-AC4B-D9A0D80C3D3BQ37415836-23A7B7FA-0447-44AF-B14E-E2122D88E490Q37572777-71143C98-4C82-4864-B580-07523D7B650FQ37717198-0623BB5D-D516-4317-858B-9F82A3AED706Q37811884-0F56AA39-1AD2-4404-B25A-A15589A62D49Q37871429-40168384-2AA1-47FB-A649-8BFADC867632Q37991400-AA6DEBE7-C5C6-4CE7-AC8D-3D83D74B6408Q37996816-CBF05556-3A5D-424D-9749-CDCA489751AEQ38000301-1340E78C-BDB9-4D27-BA0A-2B0F6DF37E28Q38015123-627DB747-8402-44F7-88E8-0FA15E646A78Q38114071-8E01F162-08E6-4B4B-B881-4D267159ECFDQ38133632-FB47BFF2-266B-4BE4-B514-9D2AD46F656CQ38560389-6D49F68F-93B6-4BDC-8C9C-0171E4ED1712Q38714989-7A542393-20B7-4E19-A88F-2E1EC37215A1Q39014899-386008D4-08C2-40D0-87AB-FE6B884AB8F2Q39015531-76E2F1E9-7420-4C54-B179-1D8F397FD2B6Q39154189-46C26EA2-335D-421D-A376-E2E8C754EE89Q39360428-87F2F8A1-A0DD-4A98-AEF1-DAA16400C9CEQ39550591-9254AA3A-6A7A-4410-88F7-FAD474E50374Q39908369-96071EDE-4C39-4031-AB0C-4BC6DEA55509Q39930816-AE8A14DD-A5D9-4CDA-A49C-B4FF9A6A39FBQ40102608-C1DC70DB-6BE2-4E50-9899-FD93ED72CFC6Q40393915-43EEDA00-8AD7-4493-B7B3-5D185DF509CDQ40458129-19625E44-33F5-47E7-B5FC-DA78F7D68891Q40499853-C676E724-75D4-4075-8D44-E25782B78182Q40516749-01AED709-3A03-4A3A-9044-62AA9E11D281Q40700453-8041594C-227E-4A1D-A92E-4C382946DD63Q40733554-6822A703-6EB4-412B-B313-AC8D451CE3CE
P50
description
investigador
@es
researcher
@en
name
Zwi N Berneman
@en
Zwi N Berneman
@nl
type
label
Zwi N Berneman
@en
Zwi N Berneman
@nl
prefLabel
Zwi N Berneman
@en
Zwi N Berneman
@nl
P31
P496
0000-0002-9133-4588